 DehydraTECH-oral nicotine delivery peaked in bloodstream 10x to 20x faster than controls Peak levels achieved were up to 10x higher than controls KELOWNA, BC ACCESSWIRE October 5, 2021 Lexaria Bioscience Corp. NASDAQ:LEXXNASDAQ:LEXXW the Company or Lexaria, a global innovator in drug delivery platforms is pleased to announce that its recent oral nicotine absorption study NIC-A21-1 revealed that DehydraTECHTM-nicotine delivered via the oral pouch product format required only 2 to 4 minutes to deliver nicotine levels in blood plasma comparable to levels achieved at 45 minutes with concentration-matched controls. DehydraTECH-nicotine also reached statistically significant peak blood plasma levels up to 10-fold higher overall than controls p0.004 while still clearing from blood virtually as quickly as the controls. 